康方生物高开逾6% 依沃西再次头对头战胜PD1单抗

新浪港股

04-24

热点栏目自选股数据中心行情中心资金流向模拟交易

客户端

　　康方生物（09926）高开逾6%，截至发稿，股价上涨6.24%，现报98.70港元，成交额6.64亿港元。

　　消息面上，康方生物宣布，依沃西联合化疗对比替雷利珠单抗联合化疗一线治疗晚期鳞状非小细胞肺癌的3期头对头临床试验期中分析显示强阳性结果：达到PFS的主要临床终点，具有统计学显著意义和重大临床获益。

　　交银国际认为，依沃西第二项头对头III期成功，进一步验证了其在肺癌领域相较PD-（L）1单靶药物的竞争优势，同时该适应症的后续报产、获批也将增厚短期业绩。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：卢昱君

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2529618395"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2529618395\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2529618395?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-04-24 09:41","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2529618395","market":"hk","top_or_hot":-1,"title":"康方生物高开逾6% 依沃西再次头对头战胜PD1单抗","media":"新浪港股","content":"<html><body><div>\n<div>\n<div>\n<img src=\"http://image.sinajs.cn/n/hk/min/640x360xxfhd/09926.png\"/>\n</div>\n<div>\n<div>\n<span>热点栏目</span>\n<s></s>\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n</div>\n客户端\n</div>\n</div>\n<p>　　<span><a href=\"https://laohu8.com/S/09926\">康方生物</a></span><span></span>（09926）高开逾6%，截至发稿，股价上涨6.24%，现报98.70港元，成交额6.64亿港元。</p>\n<p>　　消息面上，康方生物宣布，依沃西联合化疗对比替雷利珠单抗联合化疗一线治疗晚期鳞状非小细胞肺癌的3期头对头临床试验期中分析显示强阳性结果：达到PFS的主要临床终点，具有统计学显著意义和重大临床获益。</p>\n<p>　　<span><a href=\"https://laohu8.com/S/03329\">交银国际</a></span><span></span>认为，依沃西第二项头对头III期成功，进一步验证了其在肺癌领域相较PD-（L）1单靶药物的竞争优势，同时该适应症的后续报产、获批也将增厚短期业绩。</p>\n<div></div>\n<div>\n<div><img src=\"\"/></div>\n<div>海量资讯、精准解读，尽在新浪财经APP</div>\n</div>\n<p>责任编辑：卢昱君 </p>\n</div></body></html>","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康方生物高开逾6% 依沃西再次头对头战胜PD1单抗</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康方生物高开逾6% 依沃西再次头对头战胜PD1单抗\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-24 09:41 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-04-24/doc-ineufnky2442785.shtml><strong>新浪港股</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　康方生物（09926）高开逾6%，截至发稿，股价上涨6.24%，现报98.70港元，成交额6.64亿港元。\n　　消息面上，康方生物宣布，依沃西联合化疗对比替雷利珠单抗联合化疗一线治疗晚期鳞状非小细胞肺癌的3期头对头临床试验期中分析显示强阳性结果：达到PFS的主要临床终点，具有统计学显著意义和重大临床获益。\n　　交银国际...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-04-24/doc-ineufnky2442785.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-04-24/doc-ineufnky2442785.shtml","article_id":"2529618395","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2529618395","pubTimestamp":1745458860,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"　　康方生物高开逾6%，截至发稿，股价上涨6.24%，现报98.70港元，成交额6.64亿港元。　　交银国际认为，依沃西第二项头对头III期成功，进一步验证了其在肺癌领域相较PD-1单靶药物的竞争优势，同时该适应症的后续报产、获批也将增厚短期业绩。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{},"translate_title":"Akeso Bio opened more than 6% higher, Ivoxi once again defeated PD1 monoclonal antibody head-to-head","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　康方生物（09926）高开逾6%，截至发稿，股价上涨6.24%，现报98.70港元，成交额6.64亿港元。\n　　消息面上，康方生物宣布，依沃西联合化疗对比替雷利珠单抗联合化疗一线治疗晚期鳞状非小细胞肺癌的3期头对头临床试验期中分析显示强阳性结果：达到PFS的主要临床终点，具有统计学显著意义和重大临床获益。\n　　交银国际认为，依沃西第二项头对头III期成功，进一步验证了其在肺癌领域相较PD-（L）1单靶药物的竞争优势，同时该适应症的后续报产、获批也将增厚短期业绩。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}